Cheng Hao, Yu Jun, Wong Chi Chun
Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, SAR 518172, China.
Protein Cell. 2025 Jun 20;16(6):391-417. doi: 10.1093/procel/pwae039.
Adenosine-to-inosine (A-to-I), one of the most prevalent RNA modifications, has recently garnered significant attention. The A-to-I modification actively contributes to biological and pathological processes by affecting the structure and function of various RNA molecules, including double-stranded RNA, transfer RNA, microRNA, and viral RNA. Increasing evidence suggests that A-to-I plays a crucial role in the development of human disease, particularly in cancer, and aberrant A-to-I levels are closely associated with tumorigenesis and progression through regulation of the expression of multiple oncogenes and tumor suppressor genes. Currently, the underlying molecular mechanisms of A-to-I modification in cancer are not comprehensively understood. Here, we review the latest advances regarding the A-to-I editing pathways implicated in cancer, describing their biological functions and their connections to the disease.
腺苷到肌苷(A-to-I)是最普遍的RNA修饰之一,最近备受关注。A-to-I修饰通过影响各种RNA分子的结构和功能,包括双链RNA、转运RNA、微小RNA和病毒RNA,积极参与生物和病理过程。越来越多的证据表明,A-to-I在人类疾病尤其是癌症的发展中起关键作用,异常的A-to-I水平通过调节多个癌基因和肿瘤抑制基因的表达与肿瘤发生和进展密切相关。目前,癌症中A-to-I修饰的潜在分子机制尚未完全明确。在此,我们综述了与癌症相关的A-to-I编辑途径的最新进展,描述了它们的生物学功能及其与疾病的联系。